期刊
CANCER
卷 124, 期 10, 页码 2086-2103出版社
WILEY
DOI: 10.1002/cncr.31272
关键词
checkpoint inhibitors; immunotherapy; programmed cell death-1 (PD-1) receptor; programmed death-ligand 1 (PD-L1); triple-negative breast cancer
类别
资金
- Shifrin-Myers Breast Cancer Discovery Fund
- New York State Department of Health Peter T. Rowley Breast Cancer Projects [DOH01-Rowley-2015-00,076]
Advances in cancer immunotherapy and a growing body of research have focused on the role of the antitumor response in breast cancer. Triple-negative breast cancer (TNBC) is the most immunogenic breast cancer subtype, and there is strong evidence that tumor-infiltrating lymphocytes in TNBC have prognostic value and are associated with clinical outcome and improved survival. Evading antitumor immunity is a hallmark for the development and progression of cancer. Immunotherapy studies have focused on the role of the programmed cell death-1 (PD-1) receptor/programmed death-ligand 1 (PD-L1) pathway in maintaining immunosuppression in the tumor microenvironment. Blockade of the PD-1/PD-L1 axis has emerged as a promising therapeutic option to enhance antitumor immunity and is actively being investigated in TNBC, with encouraging results. In this article, the authors review the current literature on checkpoint inhibitors in TNBC with a focus on PD-1/PD-L1 antibodies and discuss combination strategies and novel approaches for improving antitumor immunity and clinical outcome. (C) 2018 American Cancer Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据